Jundishapur Journal of Microbiology

Published by: Kowsar

In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey

Gulgun Yenisehirli 1 , * , Nermin Bulut 1 , Aydan Yenisehirli 2 and Yunus Bulut 1
Authors Information
1 Department of Microbiology and Clinical Microbiology, Faculty of Medicine, Gaziosmanpasa University, Tokat, Turkey
2 Department of Pharmacology, Faculty of Medicine, Gaziosmanpasa University, Tokat, Turkey
Article information
  • Jundishapur Journal of Microbiology: September 2015, 8 (9); e59898
  • Published Online: September 8, 2015
  • Article Type: Research Article
  • Received: February 18, 2015
  • Revised: June 9, 2015
  • Accepted: June 16, 2015
  • DOI: 10.5812/jjm.28057

To Cite: Yenisehirli G, Bulut N, Yenisehirli A, Bulut Y. In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey, Jundishapur J Microbiol. 2015 ; 8(9):e59898. doi: 10.5812/jjm.28057.

Abstract
Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Lopez J, et al. Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect. 2011; 77(2): 157-61[DOI][PubMed]
  • 2. Holzheimer RG, Dralle H. Management of mycoses in surgical patients -- review of the literature. Eur J Med Res. 2002; 7(5): 200-26[PubMed]
  • 3. Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009; 52(3): 197-205[PubMed]
  • 4. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20(1): 133-63[DOI][PubMed]
  • 5. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998; 11(2): 382-402[PubMed]
  • 6. Masia Canuto M, Gutierrez Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis. 2002; 2(9): 550-63[PubMed]
  • 7. Mukherjee PK, Sheehan D, Puzniak L, Schlamm H, Ghannoum MA. Echinocandins: are they all the same? J Chemother. 2011; 23(6): 319-25[DOI][PubMed]
  • 8. Grant SM, Clissold SP. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990; 39(6): 877-916[PubMed]
  • 9. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore). 2003; 82(5): 309-21[DOI][PubMed]
  • 10. Nguyen MH, Yu CY. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother. 1998; 42(2): 253-6[PubMed]
  • 11. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006; 50(6): 2009-15[DOI][PubMed]
  • 12. Badiee P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran J Microbiol. 2011; 3(4): 183-8[PubMed]
  • 13. Rogers TR, Johnson EM, Munro C. Echinocandin antifungal drug resistance. J Invasive Fungal Infect. 2007; : 199-205
  • 14. Nelson PW, Lozano-Chiu M, Rex JH. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. J Med Vet Mycol. 1997; 35(4): 285-7[PubMed]
  • 15. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol. 2006; 44(3): 760-3[DOI][PubMed]
  • 16. Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol. 2006; 44(2): 324-6[DOI][PubMed]
  • 17. Baixench MT, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother. 2007; 59(6): 1076-83[DOI][PubMed]
  • 18. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002; 359(9312): 1135-44[DOI][PubMed]
  • 19. Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol. 2002; 40(10): 3841-4[PubMed]
  • 20. Pfaller MA, Messer SA, Mills K, Bolmstrom A, Jones RN. Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species. J Clin Microbiol. 2001; 39(11): 3952-4[DOI][PubMed]
  • 21. Pfaller MA, Messer SA, Bolmstrom A. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn Microbiol Infect Dis. 1998; 32(3): 223-7[PubMed]
  • 22. Pfaller MA, Messer SA, Mills K, Bolmstrom A, Jones RN. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J Clin Microbiol. 2001; 39(12): 4387-9[DOI][PubMed]
  • 23. Larone D. Medically important fungi: a guide to identification. 2002;
  • 24. Clinical and Laboratory Standards Institute . Reference method for broth dilution antifungal susceptibility testing of yeasts; Fourth informational supplement. . 2012;
  • 25. Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca-Estrella M, Diekema DJ, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol. 2012; 50(6): 2040-6[DOI][PubMed]
  • 26. Candido RC, Toloi MR, Franceschini SA, Garcia FR, Minto EC. In vitro activity of antimycotic agents determined by E-test method against vaginal Candida species. Mycopathologia. 1998; 144(1): 15-20[PubMed]
  • 27. Bicmen C, Doluca M, Gulat S, Gunduz AT, Tuksavul F. Species level identification and antifungal susceptibility of yeasts isolated from various clinical specimens and evaluation of Integral System Yeasts Plus. New Microbiol. 2012; 35(3): 327-34[PubMed]
  • 28. Fleck R, Dietz A, Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother. 2007; 59(4): 767-71[DOI][PubMed]
  • 29. Faria-Ramos I, Neves-Maia J, Ricardo E, Santos-Antunes J, Silva AT, Costa-de-Oliveira S, et al. Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey. Eur J Clin Microbiol Infect Dis. 2014; 33(12): 2241-7[DOI][PubMed]
  • 30. Bourgeois N, Dehandschoewercker L, Bertout S, Bousquet PJ, Rispail P, Lachaud L. Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods. J Clin Microbiol. 2010; 48(1): 154-61[DOI][PubMed]
  • 31. Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol. 2009; 47(6): 1942-6[DOI][PubMed]
  • 32. Santhanam J, Nazmiah N, Aziz MN. Species distribution and antifungal susceptibility patterns of Candida species: Is low susceptibility to itraconazole a trend in Malaysia? Med J Malaysia. 2013; 68(4): 343-7[PubMed]
  • 33. Zarei Mahmoudabadi A, Zarrin M, Beheshti Fard M. Antifungal susceptibility of Candida species isolated from candidura. Jundishapur J Microbiol. 2012; 6(1): 24-8[DOI]
  • 34. Zarei Mahmoudabadi A, Zarrin M, Kiasat N. Biofilm Formation and Susceptibility to Amphotericin B and Fluconazole in Candida albicans. Jundishapur J Microbiol. 2014; 7(7)[DOI][PubMed]
  • 35. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods. J Clin Microbiol. 2007; 45(1): 70-5[DOI][PubMed]
  • 36. Santos ER, Dal Forno CF, Hernandez MG, Kubica TF, Venturini TP, Chassot F, et al. Susceptibility of Candida spp. isolated from blood cultures as evaluated using the M27-A3 and new M27-S4 approved breakpoints. Rev Inst Med Trop Sao Paulo. 2014; 56(6): 477-82[PubMed]
  • 37. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol. 2008; 46(2): 551-9[DOI][PubMed]
  • 38. Shokohi T, Bandalizadeh Z, Hedayati MT, Mayahi S. In vitro antifungal susceptibility of Candida species isolated from orofaringeal lesions of patients with cancer to some antifungal agents. Jundishapur J Microbiol. 2011; 4: 19-26
  • 39. Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol. 2014; 52(3): 994-7[DOI][PubMed]
  • 40. Cartledge JD, Midgley J, Gazzard BG. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis. AIDS. 1997; 11(15): 1839-44[PubMed]
  • 41. Haddadi P, Zareifar S, Badiee P, Alborzi A, Mokhtari M, Zomorodian K, et al. Yeast colonization and drug susceptibility pattern in the pediatric patients with neutropenia. Jundishapur J Microbiol. 2014; 7(9)[DOI][PubMed]
  • 42. Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994; 38(7): 1530-3[PubMed]
  • 43. Arendrup MC, Pfaller MA, Danish Fungaemia Study G. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob Agents Chemother. 2012; 56(7): 3965-8[DOI][PubMed]
  • 44. Ghahri M, Mirhendi H, Zomorodian K, Kondori N. Identification and antifungal susceptibility patterns of Candida strains isolated from blood specimens in Iran. Arch Clin Infect Dis. 2013; 8(3): 14529
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments